Savara Inc.

NASDAQ:SVRA

Biotechnology

Healthcare
$4.72 +0.46%

+$0.03 today

Market cap
$1.04B
Beta
0.27
P/E (TTM)
-10.6
EPS (TTM)
-$0.51
52W Low $1.98High $7.01

Volume 5.51M

Average 1.53M

SVRA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Savara Inc.NASDAQ: SVRA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $10.73M rose 260.9% year over year, ahead of the +109.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 100.3% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +260.9% holds above the trailing-twelve-month pace of +109.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.73M+100.3% QoQ
Last fiscal yearDec 2025
$14.42M+46.3% YoY
LTMMar 2026
$22.18M+109.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+260.9%——
1 year+46.3%——
3-year CAGR+91.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
14.42M USD
Year-over-year change
+46.3%
4-year CAGR
+45.0%

Stock-Based Compensation vs competitors

How SVRA compares with its peers on the latest reported figures

  • SVRA's LTM Mar 2026 stock-based compensation of $22.18M is the largest of the 2 companies compared; the peer median is $18.1M.
  • Its year-over-year change of +109.7% is the highest of 2, against a peer median of -14.0%.
  • Over three fiscal years its annual growth of +91.9% compares with a peer median of -22.5%.
SVRA Competitors Peer median
Stock-Based Compensation for SVRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVRASavara Inc.LTM Mar 2026$22.18M +109.7%+91.9%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$18.1M -14.0%-22.5%16.5%
APMDApnimed, Inc.—— ———
Peer median (excluding SVRA) $18.1M-14.0%-22.5%16.5%

Competitors are the stored peer set for SVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.01M)(38.15M)(54.7M)(95.88M)(118.84M)
Depreciation & Amortization367K167K77K130K87K
Deferred Income Tax1.7M0000
Stock-Based Compensation3.26M2.04M4.18M9.86M14.42M
Change in Working Capital(2.85M)960K4.07M1.83M5M
Accounts Receivables00000
Inventory00000
Accounts Payables(1.76M)(319K)4.54M4.2M4.81M
Other Working Capital(1.08M)1.28M(468K)(2.37M)195K
Other Non-Cash Items449K428K(4.69M)(5.03M)(1.71M)
Operating Cash Flow(40.08M)(34.55M)(51.06M)(89.09M)(101.04M)
Capital Expenditures(57K)(9K)(296K)(25K)(22K)
Acquisitions (Net)(8.2M)056.82K00
Purchases of Investments(161.07M)(89.42M)(194.22M)(204.92M)(204.9M)
Sales of Investments91.67M142.07M137.4M165M182.2M
Other Investing Activities8.2M0(56.82K)04.28M
Investing Cash Flow(69.46M)52.65M(57.12M)(39.94M)(18.44M)
Debt Repayment088K002.37M
Common Stock Issued122.23M083.71M118.17M140.23M
Common Stock Repurchased(78K)(3K)(1.21M)(995K)(5.14M)
Dividends Paid00000
Other Financing Activities(1.35M)2K0400K0
Financing Cash Flow120.81M87K82.78M117.58M137.81M
Effect of Forex Changes(137K)(90K)(118K)(5K)(277K)
Net Change in Cash11.13M18.09M(25.52M)(11.46M)18.05M
Free Cash Flow(40.14M)(34.56M)(51.36M)(89.11M)(101.06M)

Savara Inc.

NASDAQ:SVRA

Intrinsic Alpha fair value

Locked

Current Price

$4.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.